Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities

Leukemia Research Reports

Volumn 2, Issue 2, 2013, Pages 70-74

  Dennis, M ^a   Culligan, D ^b   Karamitros, D ^c   Vyas, P ^c   Johnson, P ^d   Russell, N H ^e   Cavenagh, J ^f   Szubert, A ^g   Hartley, S ^g   Brown, J ^g   Bowen, D ^h  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h St James's Institute of Oncology   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Chemotherapy; Chromosome 5; Lenalidomide; Myelodysplasia

Indexed keywords

ANTIBIOTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; LENALIDOMIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHROMOSOME DELETION 5; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 84887969365     PISSN: 22130489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lrr.2013.07.003     Document Type: Article

References (15)

1. Fang M, Storer B, Estey E, Othus M, Zhang L, Sandmaier BM, et al. Outcome of acute myeloid leukaemia patients with monosomal karyotype who undergo hematopoietic cell transplantation. Blood 2011, 118:1490-1494.
2. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcomein patients 60 years of age or older with acute myeloid leukaemia: results from Cancer and Leukaemia Group B 8461. Blood 2006, 108(1):63-73.
3. Juliusson G, Antunovic P, Derolf A, Lehmann SR, Mollgård L, Stockelberg D, et al. Age and acute myeloid leukaemia: real world data on decision to treat and outcomes from the Swedish Acute Leukaemia Registry. Blood 2009, 113:4179-4187.
4. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine 2006, 355(14):1456-1465.
5. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, et al. for the MDS-004 Lenalidomide del5q Study GroupA randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011, 118(14):3765-3776.
6. Ades L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2-or high risk myelodysplastic syndromes (MDS) with 5q deletion: results of a phase II study. Blood 2009, 113(17):3947-3952.
7. Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukaemia: Southwest Oncology Group Study S0605. Blood 2011, 118:523-528.
8. Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. Journal of Clinical Oncology 2010, 28(33):4919-4925.
9. Möllgård L, Saft L, Treppendahl MB, Dybedal I, Nørgaard JM, Astermark J, et al. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukaemia with chromosome 5 abnormalities. Haematologica 2011, 96(7):963-971. (July).
10. Platzbecker U, Braulke F, Kündgen A, Götze K, Bug G, Schönefeldt C, et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukaemia: a phase I study. Leukaemia 2013, 27(6):1403-1407. (June).
11. Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Blood 2011 Sep 1, 118(9):2413-2419. (Epub 2011 June 20).
12. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Woll P, et al. Co-existence of LMPP-like and GMP-like Leukaemia stem cells in acute myeloid P. Cancer Cell 2011, 19:138-152.
13. Platzbecker U, Ganster C, Neesen J, Kuendgen A, Götze K, Bug G, et al. Safety and efficacy of a combination of 5-azacitidine followed by lenalidomide in high-risk MDS or AML patients with Del(5q) Cytogenetic abnormalities - Results of the "AZALE" Trial. Abstract 3799 ASH 2011.
14. Guillermo Garcia-Manero G, Daver NG, Borthakur G, Konopleva M, Ravandi F, Wierda WG, et al. Phase I study of the combination of 5-azacitidine sequentially with high-dose lenalidomide in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukaemia (AML). Abstract 2613 ASH 2011.
15. Ramsingh G, Westervelt P, Cashen A, Uy GL, Stockerl-Goldstein K, Abboud CN, et al. A phase 1 study of concomitant high dose lenalidomide and 5-azacytidine induction in the treatment of acute myeloid leukaemia. Abstract 3616, ASH 2011.